BRAIN Biotech AG Elevator Pitch 2023 | Sustainable Innovation for the Biological Age with CFO

Michael Schneiders, CFO of BRAIN Biotech AG, invites you to explore the fascinating world of biotechnology and its undeniable investment prospects. BRAIN Biotech AG, a prime standard listed company on the Frankfurt Stock Exchange since 2016, is a forward-thinking German firm that blends economic prosperity with sustainability. The company’s holistic approach to solving industrial issues has led to an impressive record: over 535 B2B products successfully launched, more than 150 industrial partnerships, 303 employees, and 50 million euros in revenue. With 30 years of biotech experience, they have a competitive edge in the industry. BRAIN Biotech is making a global impact by focusing on critical areas such as food security and improved nutrition. Their natural preservatives and plant-based protein aim to revolutionize eating habits while considering the planet's well-being. They are also advancing health and wellness through natural treatment options, salt reduction, active pharmaceutical ingredient development, and innovative wound care treatments. The company actively minimizes pollutant conduction processes by promoting urban mining and battery recycling solutions, utilizing food waste streams to create valuable products. BRAIN Biotech champions sustainable industrialization by using CO2 as feedstock, adopting enzymatic synthesis, and investing in biolubricants. At the core of BRAIN Biotech’s operations is expertise in gene and genome editing. This innovative platform technology allows them to undertake numerous sustainability projects with speed and precision across various fields, including oncology. In nutrition, the company acknowledges the need to shift food production processes to meet the needs of a growing global population projected to reach 9.8 billion by 2050. Considering the environmental and ethical implications of current production methods, BRAIN Biotech is pioneering precision fermentation, enzymatic processes, and the use of microorganisms to produce nutritionally rich and sustainable food sources. The company’s ambitious mid-term business targets reflect confidence in its mission and capabilities. They aim to double their revenue from 50 million to 100 million euros in the next four to six years, with a group EBITDA margin target of around 15%. Additionally, they plan to increase the proportion of new product sales to 30%. Investing in BRAIN Biotech AG offers numerous benefits. Investors can participate in the biological age, contribute to sustainable industrial production, and benefit from a portfolio of enabling technologies. The company’s growth is driven by megatrends in nutrition, health, and the environment, providing a clear path to profitability. As Walter Isaacson, a TIME magazine editor, put it, “molecules are becoming the new microchip,” and BRAIN Biotech embraces this vision, presenting investors with a golden opportunity to be part of this exciting journey. Other videos: ⁠Elevator Pitch⁠ ⁠Company Presentation⁠ ⁠Deep Dive Presentation⁠ ⁠Financial Results Presentation⁠ ⁠ESG Presentation⁠ T&C: This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on ⁠www.seat11a.com/legal⁠ and ⁠www.seat11a.com/imprint⁠.